Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease

Información del artículo

Abstract

Introduction

Rivastigmine transdermal patches for the treatment of Alzheimer's disease (AD) have potential benefits compared to capsules because of their sustained absorption through the skin, good local tolerability and reduction of gastrointestinal problems.

Purpose

To assess gastrointestinal and skin tolerability and the need for optimal dose titration of rivastigmine transdermal patches in Alzheimer's disease patients previously treated with oral rivastigmine.

Patients and methods

A multicenter, randomized, open-label study including patients with mild to moderate AD (DSM-IV) previously treated with rivastigmine capsules (6–12mg/day) was conducted. Patients were randomized to: continue with capsules for 3 months (n=49) or switch to rivastigmine patch without titration (9.5mg/day for 3 months; n=48), or switch to rivastigmine patch with titration (4.6mg/day for 1 month followed by 9.5mg/day for 2 months, n=43).

Results

Incidence of gastrointestinal adverse events was 6.1% in the group treated orally and 4.2% in the group treated with non-titrated patches (P=.908). Skin tolerability was good (n=15, 16.7%) without any serious adverse events registered. Patch treatment was considered very easy to use by 72% of patients compared with 30% in the group with oral treatment (P=.0005). 60% of patients were satisfied with the patch, while only 14% were satisfied with capsules (P<.0001).

Conclusions

Rivastigmine patches have a tolerability profile similar to that shown by capsules, but are associated with greater patient satisfaction.

Keywords:

Alzheimer's disease

Rivastigmine

Treatment

Tolerability

Satisfaction

Administration route

Resumen

Introducción

Los parches transdérmicos de rivastigmina para el tratamiento de la enfermedad de Alzheimer presentan posibles beneficios respecto a las cápsulas por su absorción sostenida a través de la piel, buena tolerabilidad local y reducción de problemas gastrointestinales.

Objetivo

Evaluar la tolerabilidad gastrointestinal y cutánea y la necesidad de titulación para obtener dosis óptimas de rivastigmina transdérmica en pacientes con Alzheimer previamente tratados oralmente.

Pacientes y métodos

Se llevó a cabo un estudio multicéntrico, aleatorizado y abierto que incluyó a 142 pacientes con Alzheimer de leve a moderado y previamente tratados con rivastigmina oral (6–12mg/día). La muestra fue aleatorizada a: continuar con tratamiento oral durante 3 meses (n=49); cambio al parche sin titulación (9,5mg/día durante 3 meses, n=47) o cambio al parche con titulación (4,6mg/día por 1 mes seguido de 9,5mg/día por 2 meses, n=43).

Resultados

La incidencia de efectos adversos gastrointestinales fue del 6,1% en el grupo tratado oralmente y del 4,2% en el grupo tratado con parche sin titulación (p=0,908). La tolerabilidad cutánea fue buena (n=15, 16,7%), sin observarse acontecimientos adversos graves. El tratamiento con parche fue considerado muy fácil de utilizar por el 72% de pacientes en comparación con el 30% con tratamiento oral (p=0,0005). El 60% se mostraron satisfechos con el parche, mientras que únicamente un 14% se declaró satisfecho con las cápsulas (p<0,0001).

Conclusiones

Los parches de rivastigmina presentan un perfil de tolerabilidad similar a las cápsulas y se asocian con una mayor satisfacción de los pacientes.

Palabras clave:

Enfermedad de Alzheimer

Rivastigmina

Tratamiento

Tolerabilidad

Satisfacción

Vía de administración

El Texto completo está disponible en PDF

References

[1.]

J.L. Cummings.

Alzheimer's disease.

N Engl J Med, 351 (2004), pp. 56-67

http://dx.doi.org/10.1056/NEJMra040223 | Medline

[2.]

K. Blennow, M.J. De Leon, H. Zetterberg.

Alzheimer's disease.

Lancet, 368 (2006), pp. 387-403

http://dx.doi.org/10.1016/S0140-6736(06)69113-7 | Medline

[3.]

V. Di Lazzaro, A. Oliviero, F. Pilato, E. Saturno, M. Dileone, C. Marra, et al.

Neurophysiological predictors of long term response to AChE inhibitors in AD patients.

J Neurol Neurosurg Psychiatry, 76 (2005), pp. 1064-1069

http://dx.doi.org/10.1136/jnnp.2004.051334 | Medline

[4.]

J. Birks, J. Grimley Evans, V. Iakovidou, M. Tsolaki, F.E. Holt.

Rivastigmine for Alzheimer's disease.

Cochrane Database Syst Rev, (2009),

[5.]

I.A. Lockhart, S.A. Mitchell, S. Kelly.

Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the ‘real-world’ evidence.

Dement Geriatr Cogn Disord, 28 (2009), pp. 389-403

http://dx.doi.org/10.1159/000255578 | Medline

[6.]

C.M. Spencer, S. Noble.

Rivastigmine. A review of its use in Alzheimer's disease.

Drugs Aging, 13 (1998), pp. 391-411

Medline

[7.]

P. Bar-On, C.B. Millard, M. Harel, H. Dvir, A. Enz, J.L. Sussman, et al.

Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.

Biochemistry, 41 (2002), pp. 3555-3564

Medline

[8.]

N. Tavassoli, A. Sommet, M. Lapeyre-Mestre, H. Bagheri, J.L. Montrastruc.

Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal British National Formulary).

Drug Saf, 30 (2007), pp. 1063-1071

Medline

[9.]

C. Sevilla, P.E. Jimenez Caballero, V. Alfonso, M. Gonzalez-Adalid.

Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?.

Dement Geriatr Cogn Disord, 28 (2009), pp. 196-205

http://dx.doi.org/10.1159/000236015 | Medline

[10.]

A. Wentrup, W.H. Oertel, R. Dodel.

Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.

Drug Des Devel Ther, 2 (2009), pp. 245-254

Medline

[11.]

J.L. Cummings, M.R. Farlow, X. Meng, S. Tekin, J.T. Olin.

Rivastigmine Transdermal Patch Skin Tolerability: Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease.

Clin Drug Investig, 30 (2010), pp. 41-49

http://dx.doi.org/10.2165/11531270-000000000-00000 | Medline

[12.]

M.R. Farlow, G. Alva, X. Meng, J.T. Olin.

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.

Curr Med Res Opin, 26 (2010), pp. 263-269

http://dx.doi.org/10.1185/03007990903434914 | Medline

[13.]

M.F. Folstein, S.E. Folstein, P.R. McHugh.

“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician.

J Psychiatr Res, 12 (1975), pp. 189-198

Medline

[14.]

K. Venkatesh, R. Bullock, A. Akbas.

Strategies to improve tolerability of rivastigmine: a case series.

Curr Med Res Opin, 23 (2007), pp. 93-95

http://dx.doi.org/10.1185/030079906X162791 | Medline

[15.]

M. Weiser, H.H. Rotmensch, A.D. Korczyn, R. Hartman, A. Cicin-Sain, R. Anand.

A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.

Int J Geriatr Psychiatry, 17 (2002), pp. 343-346

http://dx.doi.org/10.1002/gps.599 | Medline

[16.]

P.Y. Chiu, D.E. Dai, H.P. Hsu, C. Lee, J.J. Lin, H.C. Kuo, et al.

Safety/tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.

Clin Drug Investig, 29 (2009), pp. 729-738

http://dx.doi.org/10.2165/11315320-000000000-00000 | Medline

[17.]

B.P. Imbimbo.

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

CNS Drugs, 15 (2001), pp. 375-390

Medline

[18.]

G. Lefevre, F. Pommier, G. Sedek, M. Allison, H.L. Huang, B. Kiese, et al.

Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.

J Clin Pharmacol, 48 (2008), pp. 246-252

http://dx.doi.org/10.1177/0091270007312154 | Medline

[19.]

J.T. Olin, V. Bhatnagar, P. Reyes, B. Koumaras, X. Meng, S. Brannan.

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).

Int J Geriatr Psychiatry, 25 (2010), pp. 419-426

http://dx.doi.org/10.1002/gps.2355 | Medline

[20.]

T. Darreh-Shori, V. Jelic.

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.

Expert Opin Drug Saf, 9 (2010), pp. 167-176

http://dx.doi.org/10.1517/14740330903439717 | Medline

[21.]

C.H. Sadowsky, M.R. Farlow, L. Atkinson, J. Steadman, B. Koumaras, M. Chen, et al.

Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study.

Prim Care Companion J Clin Psychiatry, 07 (2005), pp. 43-48

[22.]

B. Winblad, G. Grossberg, L. Frolich, M. Farlow, S. Zechner, J. Nagel, et al.

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

Neurology, 69 (2007), pp. S14-S22

http://dx.doi.org/10.1212/01.wnl.0000281847.17519.e0 | Medline

[23.]

G. Grossberg, C. Sadowsky, H. Frostl, L. Frolich, J. Nagel, S. Tekin, et al.

Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.

Alzheimer Dis Assoc Disord, 23 (2009), pp. 158-164

Medline

[24.]

C.H. Sadowsky, M.R. Farlow, X. Meng, J.T. Olin.

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.

Int J Clin Pract, 64 (2010), pp. 188-193

http://dx.doi.org/10.1111/j.1742-1241.2009.02253.x | Medline

[25.]

L.F. Aguera-Ortiz, M. Ramos-Garcia, A.L. Gobartt.

A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate Alzheimer-type dementia: the SCALEX study.

Rev Neurol, 46 (2008), pp. 517-524

Medline

[26.]

I.V. Litvinenko, A.A. Sakharovskaia.

Results of the open multicenter prospective study of safety and tolerability of rivastigmine (exelon) in different titration regimes in mild and moderate Alzheimer's disease.

Zh Nevrol Psikhiatr Im S S Korsakova, 109 (2009), pp. 29-35

Medline

[27.]

B. Winblad, A.K. Kawata, K.M. Beusterien, S.K. Thomas, A. Wimo, R. Lane, et al.

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.

Int J Geriatr Psychiatry, 22 (2007), pp. 485-491

http://dx.doi.org/10.1002/gps.1806 | Medline

[28.]

J. Cummings, G. Lefevre, G. Small, S. Appel-Dingemanse.

Pharmacokinetic rationale for the rivastigmine patch.

Neurology, 69 (2007), pp. S10-S13

http://dx.doi.org/10.1212/01.wnl.0000302371.01359.c6 | Medline